MOLGRAMOSTIM
Molgramostim is a recombinant granulocyte-macrophage colony-stimulating factor (GM‑CSF) that enhances proliferation and activation of neutrophils, monocytes, and macrophages. It supports immune recovery in neutropenia and augments host defense. Side effects include fever, bone pain, injection-site reactions, leukocytosis, and rare capillary leak syndrome.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
MOLGRAMOSTIM (ID 28089) demonstrates a high‑dimensional biochemical activity framework integrating catalytic‑domain modulation, multi‑axis signalling interference, mitochondrial‑network recalibration, redox‑equilibrium restructuring, ion‑flux redistribution, membrane‑potential modulation, cytoskeletal‑architecture remodelling and transcription‑factor circuit reprogramming. The compound’s molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotide‑binding pockets, redox‑buffer matrices and polymeric scaffolding complexes—enabling influence across metabolic, genomic, structural and electrophysiological systems.
MOLGRAMOSTIM may alter phosphorylation‑flow geometry across ERK, MAPK, JNK, p38 and PI3K–AKT axes; reconfigure G‑protein signal‑state logic; redistribute Ca²⁺ microdomains; adjust IP₃/DAG signalling topology; and recalibrate cAMP–PKA amplitude. Mitochondrial effects include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, membrane‑potential polarity shifting, and ER–mitochondria stress‑signal cross‑talk integration.
High‑Precision Research Applications
- Kinome‑scale interference mapping & catalytic‑cascade modelling
- High‑resolution molecular docking & conformational‑transition prediction
- UPR/ER‑stress, mitophagy & autophagic‑flux regulatory modelling
- Multi‑omics network reconstruction: RNA‑seq, metabolomics, proteomics, phosphoproteomics
- Cytoskeletal tension‑mapping & polymer‑turnover analytics
- Advanced cell‑fate pathway modelling (apoptosis, necroptosis, ferroptosis, parthanatos)
- AI‑driven SAR/QSAR predictive compound‑performance optimisation
Toxicodynamics & Hazard Spectrum
- Rapid ROS escalation & antioxidant‑buffer collapse
- Mitochondrial fragmentation or ETC‑axis suppression
- Severe Na⁺/K⁺/Ca²⁺ ionic‑flux destabilisation
- Cytoskeletal depolymerisation & membrane‑integrity loss
- Inflammatory hyperactivation (NF‑κB, STAT, IRF signalling clusters)
- Activation of multi‑axis programmed‑cell‑death pathways
- Epigenetic drift including methylation/acetylation instability
For expert laboratory use only — not intended for biological or therapeutic exposure.
Datasheet
| Molecular Formula | C901H1402N240O257S9 |
|---|---|
| Molecular Weight | 19997.09 g/mol |
| CAS Number | 133022-44-3 |
| Storage Condition | Store at 28°C |
| Solubility | Soluble in water |
| Purity | Purity information is available upon request (COA). |
| IUPAC/Chemical Name | Recombinant granulocyte-macrophage CSF |
| InChl Key | Unavailable |
| InChl Code | Unavailable |
| References | PubChem; ChemBL; FDA; |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
